Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected with Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis

Clinical Infectious Diseases

Volumn 64, Issue 10, 2017, Pages 1328-1334

  Venkatesan, Sudhir ^a   Myles, Puja R ^a   Leonardi Bee, Jo ^a   Muthuri, Stella G ^b   Al Masri, Malak ^c   Andrews, Nick ^d   Bantar, Carlos ^e   Dubnov Raz, Gal ^f   Grardin, Patrick ^g,h   Koay, Evelyn S C ^i,j   Loh, Tze Ping ⁱ   Memish, Ziad ^c,k   Miller, Elizabeth ^d   Oliva, Maria E ^e   Rath, Barbara A ^l   Schweiger, Brunhilde ^m   Tang, Julian W ^i,n,o   Tran, Dat ^p   Vidmar, Tjasa ^q   Waight, Pauline A ^d   Nguyen Van Tam, Jonathan S ^a   more..

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MINISTRY OF HEALTH   (Saudi Arabia)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e HOSPITAL SAN MARTÍN   (Argentina)

^f SHEBA MEDICAL CENTER   (Israel)

^g Centre Hospitalier Universitaire de la Runion   (France)

^h U Mixte 134 PIMIT Processus Infectieux en Milieu Insulaire Trop (Ctr Natl de la Rech Sci 9192   (Reunion)

ⁱ NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k ALFAISAL UNIVERSITY   (Saudi Arabia)

^l Charit University Medical Center   (Germany)

^m ROBERT KOCH INSTITUTE   (Germany)

ⁿ UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^o UNIVERSITY OF LEICESTER   (United Kingdom)

^p UNIVERSITY OF TORONTO   (Canada)

^q General Hospital Slovenj Gradec   (Slovenia)

more..

Author keywords

hospitalization; individual participant data metaanalyses; influenza; neuraminidase inhibitors; pandemic

Indexed keywords

SIALIDASE INHIBITOR; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD; COMMUNITY CARE; DYSPNEA; FEMALE; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION RISK; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; ADOLESCENT; AMBULATORY CARE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INFLUENZA; INFLUENZA A VIRUS (H1N1); MIDDLE AGED; ODDS RATIO; OUTPATIENT; REGRESSION ANALYSIS; RISK FACTOR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; ENZYME INHIBITORS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; ODDS RATIO; OUTPATIENTS; REGRESSION ANALYSIS; RISK FACTORS; YOUNG ADULT;

EID: 85019093071     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix127     Document Type: Article

References (24)

1. Nguyen-Van-Tam JS, Openshaw PJ, Nicholson KG. Antivirals for influenza: where now for clinical practice and pandemic preparedness? Lancet 2014; 384:386-7.
2. Kelly H, Cowling BJ. Evidence and policy for influenza control. Euro Surveill 2014; 19:2-4.
3. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev 2014; 4:CD008965.
4. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: A systematic review and meta-Analysis in hospitalized patients. J Infect Dis 2013; 207: 553-63.
5. Muthuri SG, Venkatesan S, Myles PR, et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-Analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
6. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: A systematic review and meta-Analysis of observational studies. Ann Intern Med 2012; 156:512-24.
7. Myles P, Leonardi-Bee J, Van-Tam J, Muthuri S, Venkatesan S. A systematic review of the impact of neuraminidase inhibitor antiviral use on outcomes of public health importance during the 2009/10 (swine) influenza A/H1N1v pandemic. PROSPERO 2011. Available at: http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42011001273. Accessed 20 March 2016.
8. Hirano K, Imbens GW. The propensity score with continuous treatments. In: Applied Bayesian modeling and causal inference from incomplete-data perspectives: John Wiley & Sons, Ltd, 2004:73-84.
9. Public Health England. Influenza: The green book, chapter 19. The Stationery Office under licence from the Department of Health, 2015.
10. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: A cross-sectional serological study. Lancet 2010; 375:1100-8.
11. Cox CM, D'Mello T, Perez A, et al; Emerging Infections Programs Network. Increase in rates of hospitalization due to laboratory-confirmed influenza among children and adults during the 2009-10 influenza pandemic. J Infect Dis 2012; 206:1350-8.
12. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infect Dis 2012; 12:687-95.
13. Aoki FY, Macleod MD, Paggiaro P, et al; IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
14. Van Kerkhove MD, Vandemaele KAH, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: A global pooled analysis. PLoS Med 2011; 8:e1001053.
15. Dellagi K, Rollot O, Temmam S, et al. Pandemic influenza due to pH1N1/2009 virus: estimation of infection burden in Reunion Island through a prospective serosurvey, Austral winter 2009. PLoS One 2011; 6:e25738.
16. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther 2002; 9:199-205.
17. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin 2007; 23:2961-70.
18. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72.
19. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: A meta-Analysis of randomised controlled trials. Lancet 2015; 385:1729-37.
20. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 2008; 9:151-61.
21. Marra F, Chong M, Henry B, Patrick DM, Kendall P. Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. J Antimicrob Chemother 2014; 69:1397-406.
22. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Available at: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed 2 February 2016.
23. Public Health England. PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza (2015-16) Version 6.0. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/457735/PHE-guidance-Antivirals-influenza-2015-To-2016.pdf. Accessed 2 February 2016.
24. Academy of Medical Sciences WT. Use of neuraminidase inhibitors in influenza. Available at: http://www.acmedsci.ac.uk/policy/policy-projects/treating-influenza/. Accessed 2 February 2016.